GlassScriptPhysician profile
Mark H Genovesi
NPI 1578582292
$20,475.77
in general payments reported to CMS, 2019-2025
12 companies · $16K in 2025
The $16K reported for 2025 was more than what 96% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $211 · 2021: $243 · 2023: $935 · 2024: $2,724 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $15K · Food and Beverage: $2,854 · Travel and Lodging: $2,184 · Gift: $14.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $14,500.00 |
| Food and Beverage | $2,854.11 |
| Travel and Lodging | $2,184.22 |
| Gift | $14.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $17,910.96 | 2024-2025 | |
| Atricure, INC. | $622.74 | 2019-2025 | Atricure Cryoice Cryoablation System (Cryo2) |
| Ethicon INC. | $454.88 | 2020-2023 | Monarch Platform |
| Genzyme Corporation | $386.19 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $249.77 | 2021-2023 | Breztri |
| Ethicon US, LLC | $232.35 | 2019-2025 | Vistaseal, Surgiflo Hemostatic Matrix |
| Olympus America INC. | $144.44 | 2024 | Spin Vision Video Processor |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2019 | |
| La Jolla Pharmaceutical Company | $118.05 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $117.41 | 2019 | |
| Covidien LP | $98.75 | 2019 | |
| Lifenet Health | $15.23 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Genovesi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.